Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00841802

Chronic Rhinosinusitis With or Without Nasal Polyps Steroid Study

Glucocorticosteroid Action in Inflammatory Disease

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Northwestern University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Accepted

Summary

This is a study to evaluate the cause of chronic sinus disease. Oral steroids have long been used in the treatment of inflammatory conditions including chronic sinusitis, asthma, and arthritis. However, it is not well known exactly which patients will benefit from steroids when used in the treatment of chronic sinusitis. For some doctors, it is common practice to use these medications prior to planned sinus surgery, to lessen the inflammation and possibly help the healing process. Other doctors feel oral steroids may not be helpful in this way, and there is no conclusive data as to whether this practice has a long term benefit.

Detailed description

The purpose of this research study is to better understand how this potential treatment option, oral steroids, affects biochemical substances that have been associated with the development of chronic sinusitis and polyps. In order to do this, we need to study people with different forms of chronic sinusitis and compare them to individuals without allergies or sinus disease. We will also look at patients with chronic sinusitis who are treated with oral steroids and compare them to chronic sinus patients who have not received oral steroid therapy prior to surgery. This study may help pave the way to new treatments that address specific parts of the chronic sinus inflammatory pathway. Hypotheses 1. Oral steroid treatment of patients with CRS will lead to a correction in the inflammation that is observed in sinonasal tissues, nasal brushings, and nasal lavage. 2. Steroid induced changes in inflammation will differ in chronic sinus patients with polyps than in those without polyps. 3. Changes in inflammation will correlate with clinical variables.

Conditions

Interventions

TypeNameDescription
DRUGPrednisonePrednisone 30mg once daily x 5 days

Timeline

Start date
2008-07-01
Primary completion
2019-06-30
Completion
2019-06-30
First posted
2009-02-11
Last updated
2020-04-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00841802. Inclusion in this directory is not an endorsement.